MRI evaluation of the liver

Seminars in Liver Disease

Volumn 21, Issue 2, 2001, Pages 161-177

  Beavers, K L ^a   Semelka, R C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Contrast agents; Diagnosis; Liver; Magnetic resonance imaging

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM;

ADULT; ARTICLE; COMPUTED TOMOGRAPHY SCANNER; FEMALE; HUMAN; IMAGING SYSTEM; LIVER ABSCESS; LIVER ADENOMA; LIVER CIRRHOSIS; LIVER DISEASE; NODULAR HYPERPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; TECHNIQUE;

CONTRAST MEDIA; GADOLINIUM; HUMANS; LIVER DISEASES; MAGNETIC RESONANCE IMAGING; SENSITIVITY AND SPECIFICITY;

EID: 0034972730     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-15343     Document Type: Article

References (78)

1. Focal liver lesions: Characterization with nonenhanced and dynamic contrast material-enhanced MR imaging
2. Liver lesions detection, characterization, and effect on patient management: Comparison of single-phase spiral CT and current MR techniques
3. Contrast agents for MR imaging of the liver
4. Evaluation of a 10-minute comprehensive MR imaging examination of the upper abdomen
5. Comparison of breath-hold T1-weighted MR sequences for imaging of the liver
6. Abdominal MR imaging with a volumetric interpolated breath-hold examination
7. Hepatic MR imaging with a dynamic contrast-enhanced isotropic volumetric interpolated breath-hold examination: Feasibility, reproducibility, and technical quality
8. Abdominal MR imaging with a volumetric interpolated breath-hold examination
9. Liver
10. Malignant lesions of the liver with high signal intensity on T1-weighted MR images
11. Abdominal MR imaging: Comparison of T2-weighted fast conventional spinecho, and contrast-enhanced fast multiplanar spoiled gradient-recalled imaging
12. Islet cell tumors: Comparison of dynamic contrast-enhanced CT and MR imaging with dynamic gadolinium enhancement and fat suppression
13. Hypervascular malignant liver lesions; comparison of various MR imaging pulse sequences and dynamic CT
14. Extra hepatic abdominal imaging in patients with malignancy: Comparison of MR imaging and helical CT with subsequent surgical correlation
15. Dynamic MR imaging and early-phase helical CT for detection small intraheptic metastases of hepatocellular carcirnoma
16. Small hepatocellular carcinoma in patients with chronic liver damage: Prospective comparison of detection with dynamic MR imaging and helical CT of the whole liver
17. Solitary hepatic metastasis: Comparison of dynamic contrast-enhanced CT and MR imaging with fat-suppressed T2-weighted, breath-hold T1-weighted FLASH, and dynamic gadolinium-enhanced FLASH sequences
18. Dynamic breath-hold multiplanar spoiled gradient-recalled MR imaging with gadolinium enhancement for differentiating hepatic hemangiomas from malignancies at 1.5T
19. Hypervascular liver lesions: Differentiation of focal nodular hyperplasia from malignant tumors with dynamic gadolinium-enhanced MR imaging
20. Hepatic malignancies: Usefulness of acquisition of multiple arterial and portal venous phase images at dynamic gadolinium-enhanced MR imaging
21. Dynamic breath-hold multiplanar spoiled gradient-recalled MR imagining with gadolinium enhancement for differentiating hepatic hemangiomas from malignancies at 1.5 T
22. Spin-echo and dynamic gadolinium-enhanced FLASH MR imaging of hepatocellular carcinoma: Correlation with histopathologic findings
23. Small hepatocellular carcinoma and cavernous hemangioma; differentiation with dynamic FLASH MR imaging with Gd-DTPA
24. Focal hepatic lymphoma: Magnetic resonance demonstration using current techniques including gadolinium enhancement
25. Pyogenic hepatic abscesses: MRI findings on T1- and T2-weighted serial gadolinium-enhanced gradient-echo image
26. Hepatic hemangiomas: A multi-institutional study of appearance of T2-weighted and serial gadolinium-enhanced gradient-echo MR images
27. Perilesional enhancement of hepatic metastases: Correlation between MR imaging and histopathologic findingsinitial observations
28. Transient increased segmental hepatic enhancement distal to portal vein obstruction on dynamic gadolinium-enhanced gradient echo MR images
29. Correlation of perfusion abnormalities on CTAP and immediate postintravenous gadolinium-enhanced gradient echo MRI
30. Ultrasound and MR findings in acute Budd-Chiari syndrome with histopathologic correlation
31. Budd Chiari syndrome: Spectrum of appearances of acute, subacute, and chronic disease with magnetic resonance imaging
32. Quantative MR imaging data in the evaluation of hepatic metastases during systemic chemotherapy
33. Angiosarcoma of the liver: MR imaging pre- and postchemotherapy
34. Chemotherapy-treated liver metastases mimicking hemangiomas on MR images
35. Focal nodular hyperplasia of the liver: Assessment with contrast-enhanced Turbo-FLASH MR imaging
36. Peripheral washout: A sign of malignancy on dynamic gadolinium-enhanced MR images of focal liver lesions
37. Evaluation of malignant biliary obstruction: Efficacy of fast multiplanar spoiled gradient-recalled MR imaging vs. spin-echo MR imaging, CT and cholangiography
38. MR imaging of peritoneal disease: Comparison of contrast enhanced fast multiplanar spoiled gradient-recalled and spin-echo imaging
39. Cholangiocarcinoma: Spectrum of appearances on MR images using current techniques
40. Detection of hepatic metastases: Ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography
41. Hepatic lesion detection: Comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis
42. Hepatic MR imaging with ferumoxides: A multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions
43. Hepatic lesions: Detection with ferumoxide-enhanced T1-weighted MR imaging
44. Hepatic lesion detection at MR imaging: A comparative study with four sequences
45. Superparamagnetic iron oxide particles (SHU 555 A): Evaluation of efficacy in three doses for hepatic MR imaging
46. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: A potential new sign for characterization of liver lesions
47. MR imaging of the liver with Resovist: Safety, efficacy, and pharmacodynamic properties
48. Magnetic resonance imaging of focal liver lesions: Comparison of the superparamagentic iron oxide Resovist versus gadolinium-DTPA in the same patient
49. Contrast-enhanced MRI of focal liver lesions: Differentiation and detection of primary and secondary liver lesions using Resovist-enhanced versus gadolinium-enhanced MRI in the same patient
50. Clinical results with Resovist: A phase 2 clinical trial
51. Differentiation of hepatomas from nonhepatomatous masses: Use of MnDPDP-enhanced MR images
52. Diagnostic efficiency of Mn-DPDP in MR imaging of the liver: A phase III multi-center study
53. Mangafodipir trisodium: Effects on T2-and T1-weighted MR cholangiography
54. Focal malignant liver lesions: MR imaging enhanced with gadolinium benzoxypropionictetra-acetate (BOPTA)preliminary results of phase II clinical application
55. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: Safety, pharmacokinetics, and MR imaging
56. Liver tumors: Comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA
57. Hepatic metastases CT versus MR imaging at 1.5T
58. Malignant liver lesions: Comparison of spiral CT arterial portography and MR imaging for diagnostic accuracy, cost, and effect on patient management
59. Detection of liver metastases: Comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.ST with dynamic CT, intraoperative US, and percutaneous US
60. Comparison of gadolinium with manganese-DPDP for liver lesion detection and characterization: Preliminary results
61. Superparamagnetic iron oxide-enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions
62. Renal lesion characterization with gadolinium-enhanced MR imaging: Efficacy and safety in patients with renal insufficiency
63. Ovarian cancer: Comparison of findings with perfluorocarbon-enhanced MR imaging, In-111-SYT-103 immunoscintigraphy, and CT
64. Renal cancer staging: Comparison of contrast-enhanced CT and gadolinium-enhanced fat-suppressed spin-echo and gradient-echo MR imaging
65. Hepatic hemangiomas and malignant tumors: Improved differentiation with heavily T2W spin-echo MR imaging
66. Amebic liver abscess: Diagnosis and treatment of evaluation with MR imaging
67. Mn-DPDP enhancement characteristics and differentiation between cirrhotic and noncirrhotic livers
68. Enhanced tumor detection in the presence of liver cirrhosis: Experimental study on the diagnostic value of a superparamagnetic iron oxide MR imaging contrast agent
69. Small hepatic nodules in cirrhosis: Ultrasonographic, CT, and MR imaging findings
70. Definition of liver tumors in the presence of diffuse liver disease: Comparison of findings at MR imaging with positive and negative contrast agents
71. Magnetic resonance iron-free nodules in genetic hemochromatosis
72. Hepatic metastases and cavernous hemangiomas: Distinction with standard-and triple-dose gadoteridol-enhanced MR imaging
73. Detection of colorectal liver metastases: Prospective comparison of unenhanced and ferumoxides-enhanced magnetic resonance imaging at 1.5 T, dual-phase spiral CT, and spiral CT during arterial portography
74. Diagnosis of liver metastases from colorectal carcinoma: Comparison of spiral-CTAP combined with intravenous contrast-enhanced spiral CT and SPIO-enhanced MR combined with plain MR imaging
75. Small hepatocellular carcinoma: Differentiation from adenomatous hyperplasia with color Doppler US and dynamic Gd-DTPA-enhanced MR imaging
76. Treatment of hepatocellular carcinoma with percutaneous ethanol injection: Evaluation with contrast-enhanced MR imaging
77. Dynamic MR follow-up of small hepatocellular carcinoma after percutaneous ethanol injection therapy
78. Small hepatocellular carcinoma treated with percutaneous ethanol injection: Unenhanced and gadolinium-enhanced MR imaging follow-up